Strategic Buys Fuel MAb Developer Immune Pharma
In less than three years, privately held Immune Pharmaceuticals has matured from a start-up launched with a single monoclonal antibody (MAb) licensed from Canada's iCo Therapeutics Inc. into a biotech capable of absorbing the assets of publicly traded EpiCept Corp. in an all-stock deal.
Immune, which has joint headquarters in Herzliya-Pituach, Israel, and New York, is advancing lead compound bertilimumab, a fully human MAb that targets eotaxin, in the initial inflammatory bowel disease (IBD) indications of ulcerative colitis (UC) and Crohn's disease.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST